Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Oct 22;72(15):2033-42.
doi: 10.2165/11640860-000000000-00000.

Phentermine and Topiramate Extended Release (Qsymia™): First Global Approval

Affiliations

Phentermine and Topiramate Extended Release (Qsymia™): First Global Approval

Fiona Cameron et al. Drugs. .

Abstract

Vivus' proprietary oral capsule containing phentermine and extended-release (ER) topiramate has been approved in the US for the treatment of obesity. Phentermine is an appetite suppressant, while topiramate is an anti-epileptic medication. The once-daily formulation, known as Qsymia™, is designed to produce weight loss by decreasing appetite and increasing satiety. The product is also in clinical development for sleep apnoea syndrome and type 2 diabetes mellitus. This article summarizes the milestones in the development of phentermine/topiramate ER leading to this first approval for obesity.

Similar articles

See all similar articles

Cited by 6 articles

See all "Cited by" articles

References

    1. J Am Diet Assoc. 2007 Oct;107(10):1755-67 - PubMed
    1. Diabetes Care. 2007 Jun;30(6):1480-6 - PubMed
    1. Dis Model Mech. 2012 Sep;5(5):621-6 - PubMed
    1. Int J Epidemiol. 2011 Aug;40(4):985-96 - PubMed
    1. Am J Clin Nutr. 2012 Feb;95(2):297-308 - PubMed

MeSH terms

LinkOut - more resources

Feedback